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Summary The heterogeneity of therapeutic modalities and eligibility criteria and the lack of long-term follow-up in most reports of
neoadjuvant chemotherapy for breast cancer preclude us from drawing conclusions about its value in clinically relevant patient subgroups.
The present study aims to identify predictive and prognostic factors in 107 non-inflammatory stage 11/Ill breast cancer patients treated
between November 1980 and October 1991 with an anthracycline-based induction regimen before locoregional surgery. Preoperative
chemotherapy comprised 3-6 cycles of doxorubicin (pirarubicin after 1986), vindesine, cyclophosphamide and 5-fluorouracil. Type of
subsequent surgery and adjuvant treatment were decided individually. In analysis of outcome, univariate comparisons of end points were
made using the log-rank test, and significant (P 5 0.05) pre- and post-therapeutic factors were incorporated in a Cox multivariate analysis.
With a median follow-up of 81 months (range 32-164+ months), the median disease-free survival (DFS) is 90.5 months while median overall
survival has not yet been reached. Cytoprognostic grade and histopathological response in both the primary and lymph nodes were
independent covariates associated with locoregional relapse with or without DFS and overall survival. Eleven patients with pathological
complete response remain free of disease with a 68-month median follow-up, while the 18 with residual microscopic disease on the specimen
showed a 60% cumulative incidence of locoregional recurrence. Despite encouraging response rates based on clinical or radiological
evaluation (87% or 70%), neither method showed any significant correlation with pathological response and failed to contribute prognostic
information on patients' outcome. Pathological evaluation of antitumoral activity of primary chemotherapy remains a major source of
prognostic information and might be used to select patients in need of additional adjuvant treatment.
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Neoadjuvant chemotherapy was introduced in the management of
patients with locoregionally advanced breast carcinoma [i.e. stage
III Union Intemationale Contre le Cancer (UICC) (Beahrs et al,
1993)] in the 1970 decade (De Lena et al, 1978) as these patients
had a poor prognosis with 5-year survival rates of 10-20% if
treated with surgery and/or radiotherapy alone (Fletcher, 1972;
Zucali et al, 1976). According to the concept of relationship
between tumour burden and curability, this strategy was based on
the theoretical advantage of acting without delay on potential
systemic disease and added to the arguments for in vivo chemosen-
sitivity testing (Feldman et al, 1986) and for better cosmetic and
psychological results as a result of conservative breast surgery
procedures (Hortobagyi et al, 1988; Valagussa et al, 1990; Fisher
and Mamounas, 1995). Adjuvant chemotherapy was simultane-
ously developed, and the meta-analysis ofthe Early Breast Cancer
Trialists' Collaborative Group (EBCTCG, 1992) confirmed its
interest in stage I/II tumours - clinical staging and number of
axillar lymph nodes involved still remaining the most determinant
in the systemic adjuvant treatment selection (Henderson, 1991).
Received 9 July 1996
Revised 27 November 1996
Accepted 4 December 1996
Correspondence to: E Brain, CentreGeorges-Fran9ois Leclerc,
Department d'Oncologie M6dicale 3eme, 1 Rue du Professeur Marion, 21034
Dijon cedex, France
Mostneoadjuvant chemotherapy datain breast cancer are single-
centerexperiences, often lacking long-term follow-up (Swain et al,
1987; Mansi et al, 1989; Bonadonna et al, 1990; Valagussa et al,
1990; Mauriac et al, 1991; Fisher et al, 1994; Schwartz et al, 1994;
Semiglazov etal, 1994; Smith etal, 1995; van derWall etal, 1996).
In spite of cosmetic advantages and gratifying clinical response
rates, evaluation and comparison of these results remain difficult
on account of heterogeneous populations, sometimes including
inflammatory breast cancer in theircohorts, with different response
evaluation methods (combination of physical examination,
mammography and echography) and adjuvant treatment selections
(Schaake-Koning et al, 1985; Feldman et al, 1986; Rouesse et al,
1986; Swain et al, 1987; Mansi et al, 1989; Jacquillat et al, 1990;
Maloisel et al, 1990; Valagussa et al, 1990; van der Wall et al,
1996). Furthermore systematic pathological assessment of
chemotherapy results in the primary tumour has often been limited
(Jacquillat et al, 1990; Mauriac et al, 1991) or obtained by multiple
biopsies (Feldman et al, 1986; Swain etal, 1987; Mansi etal, 1989;
Smith et al, 1995). Consequently, there are neither acknowledged
techniques for evaluation of the response nor established prog-
nostic variable consensus for this modality of primary manage-
ment, nor any validated means to gauge its real contribution to end
points as time to progression, disease-free survival (DFS) and
overall survival (OS) (Fisher and Mamounas, 1995).
We present a retrospective analysis on 107 women with stage
IL/Ill non-inflammatory breast carcinoma treated between
November 1980 and October 1991 with an anthracycline-based
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neoadjuvant chemotherapy followed by surgery. As assessment of
antitumoral activity was clinical, radiological and histopatholog-
ical, the study allowed comparisons of their respective value.
These results, added to the 7-year median duration of follow-up,
make this analysis important in identification of predictive and
prognostic parameters likely to assist in the prospective evaluation
design of primary cytoreduction in clinically defined localized
breast cancer.
PATIENTS AND METHODS
Patients
Candidates to neoadjuvant chemotherapy were patients with cyto-
logically or histologically confirmed stage I/III (UICC) breast
carcinoma. Premenopausal and perimenopausal women, defined
respectively by regular menstrual cycles and amenorrhoea for less
than 1 year, were included in the same group of patients for the
purposes of this analysis. Informed consent was obtained in all
cases according to institutional guidelines.
Pretreatment evaluation
Patients had a detailed clinical history and physical examination.
Diagnosis was usually performed on fine-needle aspiration
cytology. Whenever possible, steroid hormone receptor status
(oestrogen receptor, ER and progesterone receptor, PR) was estab-
lished. Cytoprognostic grade was determined on an accepted and
validated correspondence with the Scarff, Bloom and Richardson
histopathological grading (De Maublanc, 1991). Absence of clin-
ical metastasis was ascertained through a systematic work-up
consisting of chest roentgenogram, bone scan and liver ultra-
sonography. Bilateral mammography completed clinical staging.
Electrocardiogram, haemogram and blood biochemistry with
liver function tests were performed before starting induction
chemotherapy.
Treatment
Neoadjuvant chemotherapy was based on an AVCF-type regimen
(Rouesse et al, 1986): doxorubicin 40 mg m-2 day 1, vindesine 2
mg m-2 day 2, cyclophosphamide 350 mg m-2 day-' and fluo-
rouracil 400 mg m-3 day -' by short (20-60 min) i.v. in fusion from
day 1 to day 4. Folinic acid 150 mg m-2 day -' preceeded the fluo-
rouracil administration in 50% of patients. After 1986, doxoru-
bicin was replaced by an analogue: pirarubicin (Theprubicine,
Bellon, Neuilly/Seine, France) 20 mg m-2 day-' given day 1 to day
3. In absence of progression, patients were given chemotherapy
every 4 weeks until no additional objective decrease in clinical
size of tumour or nodes occurred. The protocol planned a
maximum amount of six cycles before surgery. In case of World
Health Organisation (WHO) grade III/IV extra-haematological
side-effects (Miller et al, 1981), chemotherapy had to be discon-
tinued and patients had to undergo surgery.
After primary chemotherapy completion, the choice of surgical
procedure [modified radical mastectomy (MRM) or partial
mastectomy] was decided individually by the collaborating
surgeon. Homolateral axillary lymph node dissection was
required. If breast-conservation surgical procedure was chosen,
frozen-section examination informed of resection margins to
provide 2-cm clearance and to remain cosmetically acceptable. If
impossible on account of the width of the excision required,
mastectomy was chosen.
Post-operative treatment was the responsibility of the indi-
vidual, participating oncologists and there were no imposed guide-
lines. However, generally post-menopausal women received
adjuvant tamoxifen for 2 years, while premenopausal patients with
ER+ were subjected to hormonal (LHRH agonists) or surgical
castration. Depending on the number of courses administered
during primary chemotherapy, two or three cycles of the same
combination could be given as adjuvant treatment, mainly in
responding patients with positive lymph nodes. The decision to
undertake locoregional radiotherapy (remaining breast and lymph
nodes areas) was left to the responsible oncologist.
Evaluation of response
Clinical patients' status was assessed at each chemotherapy
session and before surgery as specified by WHO guidelines
(Miller et al, 1981). Mammography was performed at the begin-
ning and at the end of induction treatment. A partial remission
(PR) implied a greater than 50% reduction of the product of the
largest perpendicular diameters ofmeasurable lesions, without the
appearance of new lesions. Complete response (CR) was defined
as complete disappearance ofthe initial tumour mass. Patients not
fulfilling the criteria for CR or PR and without evidence of
increase in tumour size or new areas of involvement had stable
disease (SD).
We described histopathological response according to the
Postsurgical Treatment Pathologic Classification given by the
UICC (Beahrs et al, 1993), distinguishing pathological complete
response (pCR) in primary (pTO) and lymph nodes (pNO) from
other responses (pT+ or pTl-pT4, pN+). However, in some cases,
we could not classify response in the primary tumour within the
categories of the above-mentioned guidelines as their specimens
showed residual tumour consisting of persistance of more or less
diffuse scattered tumour cells microfoci with massive tumoral
necrosis and areas of fibrosis. We coded such reports as pT9 in
our database.
Follow-up study
Aftercompletion ofall treatment, patients were carefully followed
up every 3 months for 3 years, every 6 months during the next 2
years, then at least yearly. Work-up including mammography and
chest radiographs was carried out every 6 months at the beginning,
then once a year. Sites of initial tumour relapse were classified as
locoregional (whether exclusive or associated to distant recur-
rence) and distant (isolated and mixed). The database update was
closed on 30 June 1994, at which time all living patients had been
seen during the previous year.
Method of analysis
Correlations between histopathological response, recurrence and
main patient and tumoral characteristics were assessed with the
Pearson Chi-square test. Estimates forlocal, metastatic andoverall
DFS, and OS were calculated from the date ofdiagnosis using the
method of Kaplan and Meier (Kaplan and Meier, 1958).
Univariate comparisons ofendpoints were made with the log-rank
statistic (Mantel, 1966), and a Cox survival model (Cox, 1972)
was used to estimate the hazard ratio ofevents.
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Table 1 Pretreatment patient characteristics (n = 107)
Characteristics
Median age (years)(range)
Menopausal status
Premenopausala
Post-menopausal
Clinical size of tumour
Tl
T2
T3
T4
Tx
Clinical lymph node status
NO
Nl
N2
Clinical stage of the disease
IIA
IIB
IIIA
IIIB
x
Cytoprognostic grade
1
2
3
Not available
Hormonal receptor status
ER-PR-
ER-PR+
ER+PR+
ER+PR-
Not available
No. of patients (%)
52 (28-78)
50 (46.7)
57 (53.3)
3 (2.8)
51 (47.7)
44(41.1)
8 (7.5)
1 (0.9)
60 (56.1)
37 (34.6)
10 (9.3)
39 (36.4)
33 (30.8)
26 (24.3)
8 (7.5)
1 (0.9)
14 (13.1)
43 (40.2)
33 (30.8)
17 (15.9)
32 (29.9)
4 (3.7)
38 (35.5)
18 (16.8)
15 (14.0)
alncluding five perimenopausal patients.
RESULTS
Patient characteristics
From November 1980 to October 1991, 125 women were entered
in this study, of whom only three had stage I tumours and eight
presented inflammatory breast cancer. These patients were
excluded from analysis on account oftheir different natural history
and prognosis (Henderson, 1991), in addition to seven other
patients refusing surgery after induction chemotherapy. Thus, of
125 patients, 107 (86%) with stage II/III non-inflammatory breast
carcinoma and who underwent primary chemotherapy plus surgery
are considered in this report. Table 1 summarizes their main char-
acteristics.
Table 2 Distribution of patient characteristics according to different
histopathological responses in the primary tumour (n = 105)
Characteristic pTO pTl-pT3 pT9a Total
No. of patients
Menopausal status
Premenopausal
Post-menopausal
Initial clinical T
Ti
T2
T3
T4
Tx
Initial clinical N
NO
Ni
N2
Initial clinical stage
IIA
IIB
III
x
Cytoprognostic grade
1
2
3
Not available
Oestrogen receptor
status
ER-
ER+
Not available
Clinical response
Complete
Partial
Stable
Not available
Radiological response
Complete
Partial
Stable
Not available
Pathological N
pNO
pN+
11 76
5 35
6 41
0
9
1
0
1
11
0
0
9
1
1
6
1
3
4
4
3
6
5
0
0
2
3
1
5
39
30
6
0
40
28
8
27
24
25
0
12
31
22
11
23
46
7
11
52
11
2
0
40
22
14
18 105b
10 50
8 55
2
2
13
1
0
8
8
2
3
7
8
0
4
10
3
9
5
4
3
50
44
7
1
59
36
10
39
32
33
1
14
41
33
17
36
55
14
8
9
1
0
2
10
2
4
25
66
12
2
4
53
25
23
11 41 11 63
0 35 7 42
apT9, pathological response not able to be classed within categories of the
Postsurgical Treatment Pathologic Classification given by the UICC (Beahrs
et al, 1993) and consisting of tumoral necrosis, areas of fibrosis with
persistance of microscopic nests and/or diffuse scattered tumour cells foci.
bPathological tumour size assessment lacking in two patients (i.e. pTx).
Treatment and toxicity
The median number ofcycles ofinduction chemotherapy adminis-
tered every 4 weeks per patient was six (range two to six), without
dose reduction in > 90% of patients. Except in cases in which
patients developed severe extra haematological toxicity (24
patients), surgery was done at the maximal clinical response
recording time, i.e. after 2, 3, 4, 5 and 6 cycles in 1, 11 (10.3%), 19
(17.8%), 17 (15.9%) and 59 (55.1%) patients respectively. Grade
II/IV myelosuppression complicated with fever requiring hospi-
talization was seen in 15 patients (14%), two patients developed
grade III acral paraesthesias to vindesine, and asymptomatic
decline in left ventricular ejection fraction in three patients moti-
vated cessation ofchemotherapy after five cycles. Digestive toler-
ance was good except in four patients who presented severe
vomiting (grade IV). Despite application of refrigerated cap,
alopecia of some degree was observed in most patients. Partial
mastectomy was the chosen surgical procedure in 37 patients
(34.6%) while 70 (65.4%) underwent MRM. After surgery, all
patients were free ofdisease.
Adjuvant treatment included hormonotherapy with tamoxifen
in 47 of 57 post-menopausal women (82.5%). Seventeen of
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Table 3 Disease outcome in patients with stage 11/Ill breast cancer (univariate analysis)
Variable n LRFa P-value Mb P-value Deaths P-value
(%) (%) (%)
Clinical T
T1/T2 54 10 (18.5) 5 (09.3) 8 (14.8)
T3/T4 52 20 (38.5) 0.008 22 (42.3) 0.00001 23 (44.2) 0.001
Clinical N
NO 60 9 (15.0) 7 (11.7) 6 (10.0)
N1/N2 47 21 (44.7) 0.00001 20 (42.6) 0.00001 25 (53.2) 0.00001
Clinical stage
IIA 39 5 (12.8) 3 (07.7) 4 (10.3)
IIB 33 8 (24.2) 7 (21.2) 8 (24.2)
III 34 17 (50.0) 0.0002 17 (50.0) 0.00001 19 (55.9) 0.00001
Oestrogen receptor
ER+ 56 13 (23.2) 11 (19.6) 12 (21.4)
ER- 36 10 (27.8) >0.5 12 (33.3) 0.078 16 (44.4) 0.02
Cytoprognostic grade
1-2 57 7 (12.3) 10 (17.5) 10 (17.5)
3 33 15 (45.5) 0.0001 10 (30.3) 0.039 16 (48.5) 0.0004
Clinical response
CR 26 7 (26.9) 4 (15.4) 5-(19.2)
PR 67 19 (28.4) 19 (28.4) 22 (32.8)
SD 12 4 (33.3) >0.5 4 (33.3) >0.5 4 (33.3) >0.5
Time to clinical response/Cc
s C3 68 19 (27.9) 17 (25.0) 20 (29.4)
> C3 25 7 (28.0) >0.5 6 (24.0) >0.5 7 (28.0) >0.5
Pathological T
pTO 11 0 (0.00) - 0 (0.00) 0 (0.00)
pTl-3 76 19 (25.0) 21 (27.6) 22 (28.9)
pT9 18 11 (61.1) 0.0009 6 (33.3) 0.19 9 (50.0) 0.099
Pathological N
pNO 63 11 (17.5) 10 (15.9) 8 (12.7)
pN+ 42 18 (42.9) 0.0008 17 (40.5) 0.0008 22 (52.4) 0.00001
aLRF, locoregional failures (whether exclusive or associated to distant recurrence). bM, distant metastasis (whether exclusive or associated to
locoregional recurrence). cC, cycle.
twenty-four (70.8%) premenopausal patients with ER+ underwent
castration. Locoregional irradiation was carried out in 35 patients;
in 32 of 96 (33.3%) patients showing viable tumoral cells on the
surgical specimen after either conservative surgery [16/32 women
(50%] or MRM [16/64 (25%)] and in 3 of 11 patients with a pCR.
In patients receiving radiotherapy, no chest wall infection or moist
desquamation was observed. Adjuvant chemotherapy was deliv-
ered to 30 women; in 14 of 33 (42.4%) women with cytoprog-
nostic grade 3 tumours, in 13 of 36 (36.1%) with ER- and in 23
of 42 (54.8%) with pN+. In all, adjuvant hormonotherapy was
given to 77 patients (72%) and, in 17 instances, with concurrent
chemotherapy.
Clinical and radiological response
No tumoral progression occurred during chemotherapy. In 26
patients (24.3%), a clinical CR was documented, whereas 67
patients (62.6%) presented a PR. This clinical response occurred
before the third cycle in 68 patients (64%). Stable disease was
observed in 12 patients (11.2%) (data lacking for two patients).
Radiological response assessment was available in 84 women.
Among them, five (6%) were classified as CR, whereas PR was
recorded in 54 others (64.3%). Of 18 patients with clinical CR and
mammographic assessment available, only five (27.8%) showed a
simultaneous radiological CR, illustrating the lack of correlation
between radiological and clinical evaluations.
Clinical and radiological responses were not related to
menopausal and ER status nor to cytoprognostic grade (data not
shown). There was also no significant difference according to the
anthracyclin used or initial TNM. Among 54 T1/T2 tumours, 17
(31.5%) achieved clinical CR and 28 (51.9%) PR, while CR and
PR were documented respectively in 9 (17.3%) and 38 (73.1%) of
the 52 T3/T4 tumours (P > 0.5).
Patholological response (Table 2)
Histopathological response assessment in both the primary (pT)
and lymph nodes (pN) was available in 105 of 107 (98.1%)
patients (data incomplete in two patients). Ductal carcinoma in situ
alone was never seen, whereas 19 specimens showed coexistence
of residual invasive tumour (pT+) and small foci of intraductal
carcinoma.
We observed 11 pCR (10.3%) in the primary tumour (pTO), in
all cases without microscopically involved lymph nodes (pNO).
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Figure 1 Disease-free survival according to initial clinical stage (median
follow-up 81 months). The differences between the three curves are
statistically significant (log-rank P = 0.00001). Straight sticks represent
patients at risk. Numbers in brackets are patients remaining at risk at the end
of the curves
Six ofthose eleven patients had been assessed as clinical CR, five
had been clinically classified as PR, only two showing radiological
CR. Initial clinical T and N were significantly correlated to the
attainment of a pTO status (P < .005), which was observed mostly
in early stage tumours (IIA), all with initial NO disease.
In 18 patients, pathological assessment could not be classified
within the pT categories according to the Postsurgical Treatment
Pathological Classification. Their residual tumour histopatholog-
ical pattern was coded as pT9 (see Patients and methods). Among
them, we documented 11 pNO (61.1%) (Table 2). In this small
sample, pT9 pathological assessment was found to be unrelated to
any factor other than large tumours (T3).
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Figure 2 Overall survival according to histological axillary node dissection
results (median follow-up 81 months). The difference between the curves of
the two groups of women, with or without lymph nodes involvement, is
statistically significant (log-rank P = 0.00001). Straight sticks represent
patients at risk. Numbers in brackets are patients remaining at risk at the end
of the curves
Of 60 women with clinical NO, 13 (21.7%) had pN+ after
primary chemotherapy (11 of them with more than three involved
nodes). Of37 women with Nl disease, 21 (56.8%) hadpN+. Eight
of ten patients with N2 disease had pN+. Overall, 15 patients
(14%) had more than three involved nodes. The total of women
with pNO was 63 (58.9%).
When logistic regression analysis was performed with
pretherapy patient characteristics, clinical and radiological
responses, only clinical stage IIA appeared significantly correlated
with either pNO (P = 0.0001) or pTO (P = 0.004). Of note, there
was no correlation between pathological response and clinical or
radiological response.
Table 4 Multivariate analysis according to Cox model
End points Significant prognostic P-value Relative 95% Cl
factorsa risk
Cumulative incidence of LRFb
Cytoperognostic grade (1-2/3) 0.014 3.7 1.3-10.7
pT (pT0/pT1-pT3/pT9) 0.004 4.6 1.6-13.2
pN (pNO/pN+) 0.0008 7.7 2.3-25.6
Cumulative incidence of Mc
Cytoprognostic grade (1-2/3) 0.06 2.6 0.9-7.10
T (T1-T2/T3-T4) 0.002 7.6 2-28.0
N (NO/N1-N2) 0.009 4.5 1.5-13.8
DFS
Cytoprognostic grade (1-2/3) 0.009 2.8 1.2-6.03
T (T1-T2/T3-T4) 0.014 11.5 1.6-80.5
N (NO/N1-N2) 0.008 5.4 1.5-18.7
pN (pNO/pN+) 0.004 4.6 1.6-13.1
OS
Cytoprognostic grade (1-2/3) 0.005 4.1 1.5-10.8
T (T1-T2/T3-T4) 0.012 22.4 1.9-256
N (NO/N1-N2) 0.001 15.2 2.9-77.7
pN (pNO/pN+) 0.034 5.4 1.1-25.4
aNot significant prognostic factors (1) for cumulative incidence of LRF: ER status, T, N and stage; (2) for cumulative
incidence of M: ER status, stage, pT and pN; (3) for DFS and OS: ER status, stage and pT. bLRF, locoregional failures
(whether exclusive or associated to distant recurrence). CM, distant metastasis (whether exclusive or associated to
locoregional recurrence).
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Tumour recurrence and survival
With a median follow-up of 81 months (range 32-164+ months),
we have observed 46 relapses (43%). Local relapse alone occurred
in 19 women (17.8%) (including two patients who developed
contralateral breast cancer for the purposes of the analysis); 16
(15%) developed distant metastasis as the first sign of disease
relapse, while synchronous detection of distant metastasis and
locoregional failure was seen in 11 patients (10.3%). Thirty-one
patients (29%) have died ofmetastatic breast cancer. We registered
no other causes of death. The median DFS for the cohort is 90.5
months, while median OS has not been yet reached.
Univariate analysis
Recurrence and its type and death rate were significantly related to
well-established variables such as T, N, stage and cytoprognostic
grade (Table 3), unlike menopausal status (data not shown). ER
status showed a significant correlation only with survival (P =
0.02). Ofnote, clinical response (as well as radiological) and time
to clinical response did notreach a statistically significantvalue on
failure rate. Relapse and OS were significantly related to pN
(Table 3). Among 42 patients with pN+, 17 (40.5%) developed
metastasis and 20 (47.6%) are still alive, compared with 10
(15.9%) metastatic relapses and eight (12.7%) deaths in 63 women
with pNO (P < 0.001).
Locoregional failure was significantly correlated to pT, being
unfavourable to the 18 patients with a pT9 assessment: 11(61.1%)
developed local relapse compared with only 19 of 76 (25%) with
pTl-pT3 response (P = 0.0009). Although pT failed to signifi-
cantly correlate with metastasis likelihood or survival (Table 3), all
pTOpNO patients remain free of recurrence with a median obser-
vation time of 68 months (range 38-148+ months). One of them
developed ovarian cancer after 130 months offollow-up. Presence
ofintraductal carcinoma was notassociated with incidence oflocal
recurrence; of 19 patients with this histological pattern plus
residual invasive tumour (pT+) on the surgical specimen, five
developed local relapse (26.3%) compared with 23 in the 77 other
pT+ patients (29.9%) without any intraductal component (P > 0.5).
The type of surgery and adjuvant radiotherapy does not seem to
have influenced locoregional recurrence rate. Of 32 pT+ patients
after conservative surgery, 16 only received local radiotherapy.
However, the rate of local relapse was the same whether they had
received it or not (5 of 16 in both groups, 31.3%). The same
remark is valid for adjuvant radiotherapy in the group of pT+
patients after MRM (data not shown). On the other hand, the ones
who underwent radiotherapy in this group had more often more
than three involved nodes (7 of 16 patients) compared with the
others (6 of 48). In patients who received adjuvant chemotherapy
(30 women), 12 (40%) developed distant metastasis compared
with 15 in 77 (19.5%) without post-surgical chemotherapy. Within
these two groups of patients, the former showed a relative high
frequency of tumours with ER- (43.3%), cytoprognostic grade 3
(46.7%) and/or pN+ (76.7%) compared with the second (respec-
tive rates of 29.9%, 24.7% and 26%). The same proportion of
distant metastasis was seen in women receiving adjuvant
hormonotherapy (19 of77 patients) or not (8 of30).
In patients having undergone breast conservation procedure
initially, total mastectomy seemed the mainstay treatment for
locoregional relapse alone (8 of 17 patients, not including the two
patients with contralateral breast cancer). All had salvage mastec-
tomy and radiotherapy was performed in one patient. Five patients
remain free of second failure, while three have developed distant
metastasis, their median second relapse-free interval being 15
months (range 2-44+ months). After MRM and in case of local
failure (9 of 17 patients), treatment consisted of either surgery
(two patients), radiotherapy (three patients) or a combination of
radiotherapy and surgery (three patients). One patient refused any
treatment and died later of metastatic disease. This salvage treat-
ment prevented later recurrence in only one of these women, the
others developing relapse with a median interval of 6 months
(range 2-50 months).
Figure 1 shows the actuarial DFS according to clinical staging.
Both the 5-and 10-year DFS rates are 81% for 39 stage IIA
tumours, whereas the 5-year DFS rate is 61% for 33 patients with
stage IIB tumours. Women with stage III tumours (34 patients)
have a 5-year DFS rate of40%, and their median value for DFS is
33 months. The differences between the three curves are statisti-
cally significant (P = 0.00001). In Figure 2, survival according pN
status shows 5- and 10-year OS rates of 92% and 75%, respec-
tively, in patients with pNO, while for those with either < 3 or > 3
involved nodes actuarial OS curves meet at 54 months, 5-year
OS rate is 54% and median values for OS reach about 70 months
(P = 0.00001).
Multivariate analysis\
As shown in Table 4, we failed to correlate ER status and clinical
stage with either locoregional failure rate, metastasis rate, DFS or
OS. Multivariate analysis preserved the significance of cytoprog-
nostic grade to the four above mentioned end points. Both pT and
pN were significantly correlated with locoregional failure, while
only pN contributed furtherinformation to DFS and OS. Clinical T
and N were the other significant factors associated with incidence
ofmetastasis, DFS and OS.
DISCUSSION
Although primary chemotherapy limits the possibility to study the
initial biological characteristics ofthe tumour, it has gained popu-
larity in locally advanced breast cancer in the past 15 years,
increasing potential for breast preservation (Fisher and
Mamounas, 1995). During this time, adjuvant chemotherapy
proved itself gradually (EBCTCG, 1992), and several groups
chose to deliver it in neoadjuvant setting for earlier stages
(Jacquillat et al, 1990; Fisher et al, 1994; Schwartz et al, 1994;
Semiglazov et al, 1994). Our group has been involved in this
strategy since 1980, resorting to an anthracycline-based regimen,
in agreement with its initial experience which favours their use
in adjuvant setting for premenopausal patients with pN+ (Misset
et al, 1996). After 1986, the search for new anthracyclines less
cardiotoxic than doxorubicin resulted, in France, in the availability
of pirarubicin, which was chosen according to encouraging early
results (Chevallier et al, 1992).
Our results on survival for stage II/III tumours are similar to
data from published series of preoperative chemotherapy
(Hortobagyi et al, 1988; Jacquillat et al, 1990; Schwartz et al,
1994). Furthermore, the value of DFS and OS for patients with
stage II tumours seems to favour the use of neoadjuvant
chemotherapy, with at least adelay in disease progression parame-
ters, when compared with historical experiences ofpost-operative
chemotherapy for primary operated patients (i.e. patients with
early breast cancer). The 5- and 10-year DFS rates are both 81%
for stage IIA, the5-year rate is 61% for stage IIB, which compares
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favourably with the outcome ofthe first CMF adjuvantprogramme
of the Milan Cancer Institute (Bonadonna, 1992). Nevertheless,
this comparison must be interpreted cautiously as the exact initial
pN was not known in our study, while all women included in the
Italian trial were pN+. Moreover, only a few reports have
addressed the role of neoadjuvant chemotherapy in stage II breast
cancer (67% of our patients' population) (Jacquillat et al, 1990;
Schwartz et al, 1994; Semiglazov et al, 1994).
Recognition ofhistopathological response as a significant para-
meter in determining long-term prognosis of women submitted to
primary chemotherapy appears to be the most important contribu-
tion ofthe present report, strengthening the conclusions of several
authors (Feldman et al, 1986; Hortobagyi et al, 1988; Maloisel et
al, 1990; Ragaz et al, 1994; Frye et al, 1995). Obtaining a simulta-
neous pCR in primary and lymph nodes seems a valid surrogate
end point for long-term relapse-free status. Although pT did not
reach a significant value on DFS in multivariate analysis, none of
the 11 women who achieved pTOpNO status has relapsed with a
median follow-up of 5.7 years. They did not show a specific
pretreatment characteristics distribution other than clinical stage,
all but two being stage IIA. The British Columbia Cancer Agency
reported 16 pCR (21.6%) obtained in 74 stage III tumour patients
after a 6-month ACMF induction regimen (Ragaz et al, 1994).
Among these 16 patients, they observed four relapses (25%).
Nevertheless, the significant contribution to survival of pCR
remains considerable in these locally advanced tumours as 60% of
the 58 remaining patients developed recurrence. These results are
reinforced by a Russian randomized trial comparing neoadjuvant
chemotherapy combined to radiotherapy with radiotherapy alone
before mastectomy in 271 patients with stage IIB/IIIA breast
cancer (Semiglazov et al, 1994). In the arm with both induction
treatments, they observed 30% pCR, 95% remaining free of
relapse with a median follow-up time of53 months. However, both
studies report induction chemotherapy combined to radiotherapy,
which makes itdifficult to elicit the respective roles ofboth modal-
ities in obtaining a pCR.
Our data also indicate that one should consider carefully the
method used for the pathological response evaluation. Multiple
biopsies or fine-needle aspirations as done by several investigators
(Feldman et al, 1986; Swain et al, 1987; Briffod et al, 1989; Mansi
et al, 1989; Smith et al, 1995) may be insufficient. It could
preclude identification of a clinical subpopulation with, in partic-
ular, a high cumulative incidence oflocoregional relapse, which is
reflected in our multivariate analysis giving high significance to
pT for locoregional failure rate (P = 0.004). Thus, in 18 patients
(classified as pT9), despite significant chemosensitivity patholog-
ical marks, we observed residual scattered tumoral cells microfoci,
which may reveal a contingent of tumoral cells resistant to
chemotherapy. Ofthese patients, 60% developed local recurrence,
and 50% have died from metastatic breast cancer, even when pNO
was documented. This last point is noteworthy as pNO was a
highly significant predictive factor for long DFS and OS both in
univariate and multivariate analysis. The assessment of residual
microscopic disease might erase the benefit in obtaining pNO, and
the incorporation ofthese pT9 patients to the group withputatively
beneficial histopathological downstaging, as advocated by others
(Smith et al, 1995), may still be arguable. Although the impact of
axillary lymph node dissection on survival is often questioned in
primary operated patients (Lin et al, 1993), our study emphasizes
its major prognostic information for women submitted to primary
chemotherapy, as in the last report from the MD Anderson
Hospital (Frye et al, 1995). On the otherhand, presence ofan intra-
ductal component with residual invasive tumour was not a
predictor of local relapse, contrasting with conclusions of others
(Schnitt et al, 1984). In this last report, patients had earlier stage
tumours, and treatment consisted of local excision plus radio-
therapy, which may explain the different observations.
Non-invasive methods for response evaluation (clinical and
radiological measurements) did not show any significant prog-
nostic value on patient outcome. However, the only published
report (Jacquillat et al, 1990) showing improved DFS for patients
who had a major clinical tumour regression following primary
chemotherapy cannot be compared with our study as locoregional
treatment excluded surgery. Correlation between clinical and radi-
ological response were partial and inaccurate. Like other investi-
gators (Feldman et al, 1986; Fisher et al, 1994; van der Wall et al,
1996), we failed to establish any correlation between any ofthese
two response evaluation methods and pT or pN. This incites us to
warn against the exclusive use ofboth these techniques forevalua-
tion ofthe tumour response to primary chemotherapy.
In conclusion, the timing of chemotherapy for non-metastatic
breast cancer is still debated, and results of a randomized NSABP
B-18 trial comparing four cycles of cyclophosphamide and
doxorubicin before or after surgery are eagerly awaited (Fisher et
al, 1994). However, our study supports that a pCR in both the
primary tumour and lymph nodes has a major prognostic value in
patients being treated with neoadjuvant chemotherapy for breast
cancer. The role ofsurgery oftheprimary tumour and lymph nodes
as an evaluation tool should be considered before further assump-
tions are made of its exclusion in programmes ofprimary chemo-
therapy for breast cancer.
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